Committed to innovation, Da Volterra develops microbiota protecting therapies as well as tools intended to harness potential to help prevent and cure human diseases.
Prevention of C. difficile infection & consequences of microbiota disruption in patients with hematologic malignancies
Add-on therapy to preserve the efficacy of immune checkpoint inhibitors (ICI) in cancer patients
Reduction of severe diarrheas (Grade 3-4) and other consequences due to chemotherapy-induced disruption of the microbiota
Microbiome Discovery Platform
New microbiome diagnostic tests, predictive of clinical manifestations of dysbiosis
Novel microbiome-targeted protective and interventional therapies
Over the years since inception, we have gathered a unique in-house expertise on the intestinal microbiota and its links to the different body functions, antibacterial drugs and other drugs disrupting the microbiota as well as drug delivery technologies.